Welgenaleucel: Cytokine release syndrome and chylothorax.

A 25-year-old man with diffuse large B-cell lymphoma (DLBCL) developed chylothorax, a condition characterized by the accumulation of lymphatic fluid in the chest cavity, as a result of cytokine release syndrome (CRS) during treatment with welgenaleucel. The patient had a history of various treatments for DLBCL, including surgery, chemotherapy, and radiation. After receiving welgenaleucel, he experienced symptoms such as fatigue, diarrhea, and high fever, and was diagnosed with grade 3 CRS. Treatment with tocilizumab, a medication that targets IL-6, led to significant improvement in his symptoms. The patient was discharged in stable condition and achieved complete remission of DLBCL. The CRS and chylothorax were determined to be a result of welgenaleucel treatment. [Extracted from the article]